PDF factsheet
      Z

endothelin receptor antagonist in acute heart failure for all type of patients, clinical trials results

nesiritide versus control
NSGET (comparative trial), 2000
nesiritide(0.015 and 0.030 microg/kg/min
versus
usual care
acutely decompensated heart failure requiring invasive monitoring open
Follow-up duration: <5 days
US
nesiritide versus dobutamine
PRECEDENT, 2002
NCT00270400
nesiritide(0.015 or 0.03 microg/kg/min)
versus
Dobutamine (> or =5 microg/kg/min)
Symptomatic, Decompensated CHFopen
nesiritide versus nitroglycerin
VMAC (24h), 2002
NCT00083772
nesiritideinfusion for 24 hours
versus
nitroglycerin
acutely decompensated heart failure requiring hospitalization
nesiritide versus placebo
ASCEND-HF, 2011
NCT00475852
intravenous nesiritide for 24 hours to 7 days on top of standard therapy
versus
matching placebo
Patients hospitalized for heart failure (within 24 hours of hospitalization and institution of acute IV therapy for ADHF)double-blind
Follow-up duration: 30 days
North America, Europe, Latin America, Asia-Pacific region
BNP-CARDS, 2007
NCT00186329
nesiritide as a 0.01-µg/kg/min infusion for 48 hours
versus
placebo
acute decompensated heart failure with moderate to severe renal insufficiency Double blind
Follow-up duration: 7 days
US
FUSION 2, 2008
NCT00091520
nesiritide (2 µg/kg bolus plus 0.01 µg/kg-per-minute infusion for four to six hours)
versus
placebo
patients with ACC/AHA stage C/D heart failure with two recent heart-failure hospitalizations, an ejection fraction of less than 40%, and NYHA class 4 symptoms or NYHA class 3 symptoms with creatinine clearance less than 60 mL/mindouble-blind
Follow-up duration: 12 weeks
NSGET (efficacy trial), 2000
nesiritide(0.015 and 0.030 microg/kg/min
versus
placebo
acutely decompensated heart failure requiring invasive monitoring
PROACTION, 2003
nesiritidefor at least 12h
versus
placebo
patients presenting to the ED with acutely decompensated HF and dyspnea at rest or with minimal activitydouble-blind
Follow-up duration: 30 days
USA
VMAC (intravenous neseritide), 2002
NCT00083772
intravenous nesiritidefor 3 hours
versus
placebo
acutely decompensated heart failure requiring hospitalization double-blind
USA
nesiritide versus standard care
FUSION 1, 2004
NCT00270361
nesiritide 0.005 microg/kg/min or 0.010 microg/kg/min once weekly
versus
standard care
outpatient with co-morbid advanced heart failure and renal insufficiency open
Follow-up duration: 12 weeks
tezosentan versus placebo
RITZ 4 importé, 2003
tezosentan (25 mg/h for 1 h, then 50 mg/h for 23 to 47 h)
versus
placebo
patients with acute heart failure associated with acute coronary syndromedouble-blind
Follow-up duration: 72h
RITZ-5, 2003
tezosentan (50 or 100 mg/h) for up to 24 h
versus
placebo
patients with acute congestive heart failure double-blind
Follow-up duration: 24h
VERITAS I, 2006
NCT00525707
Infusion of tezosentan (5 mg/h for 30 minutes, followed by 1 mg/h for 24 to 72 hours
versus
placebo
patients with acute heart failuredouble-blind
Follow-up duration: 7 days
Australia, Europe, Israel, and North America.
VERITAS II, 2007
NCT00525707
Tezosentan
versus
placebo
patients with acute heart failure admitted within the previous 24 hours with persisting dyspnea and a respiratory rate of 24/min or greaterdouble-blind
Follow-up duration: 7 days
Australia, Europe, Israel, and North America

  Options


in first

in second

  Filter